Ruconest
Customize your policy alerts
Sign up for all medical mutual - ohio policy alerts
Know when medical mutual - ohio releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization, medical necessity, dosing, approval durations, site-of-care management, documentation and waste reporting requirements for Ruconest when billed under the medical or pharmacy benefit for treatment of acute hereditary angioedema (HAE) attacks (types I and II).
Policy document shows Initial Effective Date and Last Revised Date of 03/19/2026 but contains no statement of clinical policy change; therefore no material change flagged.
Coverage Summary
Coverage stance: covered_with_criteria. Scope: prior authorization, medical necessity, dosing, documentation, site-of-care management, and waste reporting requirements for Ruconest when billed under the medical or pharmacy benefit for treatment of acute hereditary angioedema (HAE) attacks (Types I and II). Indicated use: Ruconest is covered for the treatment of acute HAE attacks (Types I and II) in adults and adolescents. Exclusions: prophylactic use is not approved and effectiveness for laryngeal attacks not established. Laboratory thresholds required for diagnosis/documentation include functional C1-INH protein < 50% of normal, serum C4 level < 14 mg/dL, and C1-INH level (mass) < 19.9 mg/dL. Dosing thresholds include weight cutoff 84 kilograms (50 U/kg if less than 84 kg; 4200 U if ≥84 kg) and maximum of no more than 2 doses per 24 hours with a maximum of 4200 Units per dose.
Initial Therapy Criteria — HAE Type 1 and 2 Acute Attacks
Prior authorization required
Prior authorization is required for Ruconest when billed under HCPCS codes J0596, J3490, J3590, or J9999. Submit medical records and documentation supporting the HAE diagnosis and laboratory results with the PA request; upload via the PA portal or fax per policy.
Required diagnostic documentation
Provide laboratory confirmation and clinical history to support the diagnosis: functional C1‑INH measurement, C1‑INH level (mass), and serum C4. Medical records and chart notes demonstrating clinical history must be uploaded through the PA web portal or sent by fax.
- Functional C1‑INH protein (documented < 50% of normal) OR
- Serum C4 (< 14 mg/dL) AND C1‑INH level (< 19.9 mg/dL)
- Upload medical records/chart notes via PA portal or fax
Specialist prescriber requirement
Initial approval requires Ruconest be prescribed by or in consultation with an allergist, immunologist, hematologist, or a physician who specializes in the treatment of HAE. Document the prescribing clinician or consultation in the submitted records.
- Prescriber must be or consult with an allergist, immunologist, hematologist, or HAE specialist
- Include documentation of specialist involvement in the PA submission
Allergy check
Before approval, the provider must confirm the patient does not have a known or suspected allergy to rabbits or rabbit‑derived products and document this determination in the medical record.
- Confirm and document no known or suspected rabbit allergy prior to therapy
Site of care management and restriction
When Ruconest is billed under the medical benefit, administration is restricted to non‑hospital facility‑based locations (e.g., home infusion, provider office, ambulatory infusion center) unless the patient meets site‑of‑care exception criteria. This restriction applies to initial approvals.
- Site of care restriction applies to medical‑benefit administrations for initial therapy
- Exception criteria may permit other settings if met
Continuation / Renewal Criteria
Annual specialist assessment for continuation
For continuation/renewal, the patient must have at least one annual assessment by an HAE specialist and documentation of a favorable clinical response to Ruconest (examples: decreased attack duration, rapid onset of symptom relief, complete resolution of symptoms, or decreased attack frequency or severity). Include specialist assessment notes in the PA submission.
- At least 1 annual assessment by an HAE specialist required for continuation
- Document favorable clinical response (e.g., decreased duration, rapid symptom relief, decreased frequency/severity)
Site of care management and restriction (reauthorizations)
Site‑of‑care medical necessity criteria and restrictions for medical‑benefit administrations also apply to reauthorizations and continuation of therapy; document site‑of‑care justification or exception criteria when submitting reauthorization requests.
- Site‑of‑care rules apply to reauthorizations under the medical benefit
- Provide documentation if an exception to the non‑hospital site requirement is requested
Dosing and Administration (Acute HAE Attacks)
Waste management reporting
Waste management procedures apply when Ruconest is administered by a healthcare professional and billed under J0596. Ruconest is supplied as 2100‑unit vials that contain rabbit protein; unused product and waste must be handled per the policy's waste management requirements.
- Applies when administered by a healthcare professional and billed under J0596
- Ruconest supplied as 2100 unit vials contains rabbit protein — manage unused drug/waste per policy
Applicable Codes
| J0596 | Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units |
Prior authorization required
Prior authorization is required for HCPCS codes J0596, J3490, J3590, or J9999 when Ruconest is billed. Submit medical records and documentation supporting diagnosis and required labs with the PA request; this applies to specific and unclassified codes when Ruconest is billed under those codes.
Provider Actions & Requirements
Required diagnostic documentation
Provide lab confirmations and chart notes: functional C1‑INH, C1‑INH level (mass), and serum C4 as applicable, plus clinical chart notes documenting HAE history. Upload records through the PA portal or fax per policy submission requirements.
- Functional C1‑INH (< 50% of normal) OR C4 (< 14 mg/dL) AND C1‑INH level (< 19.9 mg/dL)
- Clinical chart notes documenting recurrent angioedema or abdominal pain criteria
- Upload via PA web portal or fax
Specialist prescriber requirement
Initial approvals require the medication be prescribed by or in consultation with an allergist, immunologist, hematologist, or an HAE specialist. Document the prescribing clinician or consultation notes in the PA submission for visibility.
- Prescriber must be or consult with an allergist, immunologist, hematologist, or HAE specialist
- Include specialist documentation for initial approval
Allergy check
Prior to administration, the provider must determine and document that the patient does not have a known or suspected allergy to rabbits or rabbit‑derived products. This determination is required before approval and administration.
- Confirm and document no known or suspected rabbit allergy before administration
Site of care management and restriction
Under the medical benefit, administration of Ruconest is restricted to non‑hospital facility‑based locations (home infusion, provider office, ambulatory infusion center) unless site‑of‑care exception criteria are met. This restriction applies to administration and initial approvals; reference the policy definitions for Site of Care management for details.
- Administration restricted to non‑hospital facility‑based locations for medical‑benefit claims unless exceptions met
- See Site of Care definition in policy definitions for examples (home infusion, provider office, ambulatory infusion center)
Clinical Evidence & Background
Background: Ruconest is a recombinant C1-esterase inhibitor (C1-INH) purified from milk of transgenic rabbits and is indicated for the treatment of acute HAE attacks in adult and adolescent patients. The prescribing information notes that the effectiveness of Ruconest was not established for HAE patients with laryngeal attacks and that safety and efficacy for prophylactic therapy have not been established. Hereditary angioedema is a genetic disorder caused by deficiency or dysfunction of C1-INH, leading to recurrent nonpruritic, nonpitting subcutaneous or submucosal edema (pain, nausea, vomiting, diarrhea) and potentially life-threatening airway swelling; Type I is associated with decreased production and low functional levels, and Type II with dysfunctional inhibitor but normal antigenic level. Evidence sources cited in the policy include the Ruconest prescribing information (Salix Pharmaceuticals, April 2020) and the WAO/EAACI 2021 guideline for management of hereditary angioedema.
Unproven / Exclusions
Important: Ruconest is not approved for prophylactic use and its effectiveness has not been established for laryngeal attacks. Requests for prophylaxis or for treatment of laryngeal HAE attacks are specifically excluded by the policy and require that the requested medication not be used for these purposes.
Revision History
Policy document shows Initial Effective Date and Last Revised Date of 03/19/2026 but contains no statement of clinical policy change; therefore no material change flagged. Administrative revision dates present in header; clinical criteria remain consistent with standard Ruconest indications and exclusions.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.